Valeant Pharmaceuticals International’s (NYSE:VRX) fourth quarter 2011 earnings of 90 cents per share (excluding special items but including stock-based compensation expense) beat the Zacks Consensus Estimate by 5 cents and the year-ago earnings by 45 cents per share. Full year earnings of $2.73 per share (excluding special items but including stock-based compensation expense) were above the Zacks Consensus Estimate of $2.69 and the year-ago earnings of $1.97 per share.
Revenues for the quarter … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards